Evidence map›Paper›PMID 25861861›Full record

ReviewBiochimica et biophysica acta2015

Perspective on computational and structural aspects of kinase discovery from IPK2014.

Eric Martin, Stefan Knapp, Richard A Engh, Henrik Moebitz, Thibault Varin, Benoit Roux, Jens Meiler, Valerio Berdini, Alexander Baumann, Michal Vieth

Abstract readReview
In one paragraph

Review in Biochimica et biophysica acta, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Eric MartinNovartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, CA 94608-2916, USA.
Stefan KnappTarget Discovery Institute and Structural Genomics Consortium, University of Oxford, NDM Research Building, Roosevelt Drive, Oxford OX3 7FZ, UK.
Richard A EnghThe Norwegian Structural Biology Centre, Department of Chemistry, University of Tromsø, Tromsø, Norway.
Henrik MoebitzNovartis Institutes for BioMedical Research, Novartis Pharma AG, Postfach, CH-4002 Basel, Switzerland.
Thibault VarinEli Lilly and Company, Lilly Research Laboratories, Lilly Corporate Center, DC 1931, Indianapolis, IN 46285, USA.
Benoit RouxUniversity of Chicago, Dept. of Biochemistry & Molecular Biology, 929 E. 57th St., Chicago 60637, IL, USA.
Jens MeilerDepartment of Chemistry, Vanderbilt University, Nashville, TN 37232, USA.
Valerio BerdiniAstex Pharmaceuticals, 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, United Kingdom.
Alexander BaumannDiscoveRx Corporation, 42501 Albrae Street, Suite 100, Fremont, CA 94538, USA.
Michal ViethEli Lilly and Company, Lilly Research Laboratories, Lilly Corporate Center, DC 1931, Indianapolis, IN 46285, USA. Electronic address: vieth_michal@lilly.com.

Funding

Conformational Flexibility in Activation of Src-KinaseR01CA093577 · NCI · WEILL MEDICAL COLLEGE OF CORNELL UNIV · PI BENOIT ROUX · 2002 to 2026
$5.6M
NCI NIH HHS R01 CA093577
6 · The paper itself

Abstract

Recent advances in understanding the activity and selectivity of kinase inhibitors and their relationships to protein structure are presented. Conformational selection in kinases is studied from empirical, data-driven and simulation approaches. Ligand binding and its affinity are, in many cases, determined by the predetermined active and inactive conformation of kinases. Binding affinity and selectivity predictions highlight the current state of the art and advances in computational chemistry as it applies to kinase inhibitor discovery. Kinome wide inhibitor profiling and cell panel profiling lead to a better understanding of selectivity and allow for target validation and patient tailoring hypotheses. This article is part of a Special Issue entitled: Inhibitors of Protein Kinases.

Indexed as

Amino Acid SequenceBinding SitesComputational BiologyCSK Tyrosine-Protein KinaseHumansProtein BindingProtein ConformationProtein Kinase InhibitorsProtein KinasesProto-Oncogene Proteins c-ablsrc-Family KinasesCSK protein, humanCSK Tyrosine-Protein KinaseProtein Kinase InhibitorsProtein KinasesProto-Oncogene Proteins c-ablsrc-Family KinasesCancer cell panel profilingConformational selectionDFG in–out transitionKinase inhibition profileKinase inhibitor

Identifiers

PMID25861861
PMCPMC5105597

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.